Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting

No standard methods are recommended for patients with advanced metastatic non-small-cell lung cancer (NSCLC) experiencing progression after 2 or more lines treatment now. The aim of this retrospective study was to assess the efficacy and safety of apatinib in metastatic NSCLC patients after second-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Jiao, Li, Dai-Rong, Huang, Lu-Mi, Ji, Xiao-Hui, Wang, Dong-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739016/
https://www.ncbi.nlm.nih.gov/pubmed/31490378
http://dx.doi.org/10.1097/MD.0000000000016967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739016/
https://www.ncbi.nlm.nih.gov/pubmed/31490378
http://dx.doi.org/10.1097/MD.0000000000016967

Ejemplares similares